Q-omics provides the consensus-scored MAPK13 profile across patient tissues and cancer cell-line models. MAPK13 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAPK13 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, MAPK13 RNA expression shows 18,646 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, THCA, and KIRP as cancer lineages where MAPK13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAPK13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAPK13 survival associations across molecular data types. MAPK13 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAPK13 RNA expression–survival associations across cancer types. High MAPK13 expression shows unfavorable associations in KIRP and COAD, but favorable associations in KIRC, SKCM, SCLC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAPK13 RNA expression.
This table summarizes MAPK13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAPK13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAPK13 shows higher tumor expression in THCA, BLCA, LUAD, LUSC, UCEC and BRCA. The THCA box plot shows higher MAPK13 RNA expression in tumor versus normal tissue (log2 FC = +0.972, t-test p < 0.001).
This table shows molecular features associated with MAPK13 in patient tissues and cancer cell lines. In patient samples, MAPK13 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, MAPK13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
